Provided by Tiger Fintech (Singapore) Pte. Ltd.

BioNTech SE

114.77
+5.124.67%
Volume:662.85K
Turnover:75.20M
Market Cap:27.51B
PE:-53.01
High:115.10
Open:110.27
Low:110.19
Close:109.65
Loading ...

Berenberg Bank Sticks to Its Buy Rating for BioNTech SE (BNTX)

TIPRANKS
·
2 hours ago

BioNTech SE ADR Advances 4.7%, Outperforms Market

Dow Jones
·
11 hours ago

Why Moderna (MRNA) Stock Is Rallying Today

Insider Monkey
·
15 hours ago

Moderna Scores Legal Victory Over Pfizer, BioNTech in Patent Dispute

GuruFocus.com
·
15 hours ago

Market Chatter: Moderna Wins Patent Ruling Against Pfizer, BioNTech in German Court

MT Newswires Live
·
16 hours ago

German Court Rules Pfizer, BioNTech, Violated Moderna Covid-19 Vaccine Patent, Reuters Reports

Dow Jones
·
16 hours ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

GlobeNewswire
·
Yesterday

Positive Outlook for Evonik: Buy Rating Supported by Strong FY-25 Guidance and Cost Savings

TIPRANKS
·
Yesterday

Bayer’s Financial Challenges and Mixed Divisional Performance Lead to Hold Rating

TIPRANKS
·
Yesterday

FDA Places Hold on BioNTech’s Malaria Vaccine Trial

TIPRANKS
·
Yesterday

BioNTech - FDA Placed Clinical Hold On Ind Application & Related Phase I/IIA Clinical Trial (Nct06069544)

Reuters
·
Yesterday

BioNTech reports FDA clinical hold on Phase I/IIa trial of BNT165e

TIPRANKS
·
Yesterday

Invivyd (NasdaqGM:IVVD) Jumps 163% After Promising Phase 1/2 Trial Results For COVID-19 Antibody

Simply Wall St.
·
Yesterday

Registration is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event MPOX 2025: Navigating the Global Public Health Emergency Featuring GeoVax CEO On March 6, 2025

NewMediaWire
·
04 Mar

Five Years Since Covid-19: Revisiting Indonesia's Response and Jokowi's Lockdown Rejection

Tempo
·
04 Mar

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

PR Newswire
·
04 Mar